SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-145638
Filing Date
2022-05-10
Accepted
2022-05-10 06:48:46
Documents
14
Period of Report
2022-05-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d318515d8k.htm   iXBRL 8-K 23178
2 EX-99.1 d318515dex991.htm EX-99.1 43176
6 GRAPHIC g318515g0510021535077.jpg GRAPHIC 2993
  Complete submission text file 0001193125-22-145638.txt   205153

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA verv-20220510.xsd EX-101.SCH 2858
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE verv-20220510_lab.xml EX-101.LAB 18739
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE verv-20220510_pre.xml EX-101.PRE 11709
8 EXTRACTED XBRL INSTANCE DOCUMENT d318515d8k_htm.xml XML 3473
Mailing Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40489 | Film No.: 22907265
SIC: 2834 Pharmaceutical Preparations